Eli Lilly and Company (Lilly) has made an equity investment in Oura. With this investment, Oura will have additional capital to accelerate development of health tools, which is aligned to Oura’s conviction that the future of care will be more connected, personalized, and responsive to how people actually live.
At Oura, we believe that better health outcomes come from the daily habits, behaviors, and biometric signals that shape how people feel and function over time. We also believe that the infrastructure around medicine — the data, health insights, and daily support that can help people stay engaged and build sustainable routines — plays an essential role in helping people achieve healthier outcomes.
Health isn't defined by a single moment or metric. It's shaped continuously through sleep, activity, stress, recovery, and other physiological patterns. As more people turn to new therapies to manage chronic conditions, there's a growing opportunity to connect those treatments with real-time insights and everyday support.
That opportunity is especially clear in metabolic health. Over one hundred thousand Oura Members have already logged GLP-1 use in the Oura App, and we recently introduced GLP-1 Insights, a companion experience that combines biometric data with GLP-1-specific context to give members a broader picture of their health, connecting biometric trends with logged medication use so people can see how their routines and physiology evolve over time.
Oura is committed to building a fuller ecosystem around outcomes, one that provides the support people need throughout the care journey. This reflects the broader shift in healthcare: improving daily health outcomes through tools and experiences that keep people informed, motivated, and connected throughout their care journey.
We believe this is where healthcare is headed: more holistic, more preventative, more integrated into daily life. We're proud to be a part of building that future.